Research from the University of Oxford and the Ludwig Institute for Cancer Research has shown that the technology behind the Oxford AstraZeneca vaccine for the Corona virus has the potential to treat cancer, and scientists from the University of Oxford and the Ludwig Institute for Cancer Research are building on the success of the Oxford AstraZeneca vaccine against the Corona virus to develop a vaccine to treat cancer. Researchers have developed a two-dose therapeutic cancer vaccine using the same technology as the Corona vaccine, according to a statement from the university on its official website.
According to the statement, when the cancer vaccine was tested in mouse tumor models, the cancer vaccine increased levels of antitumor-infiltrating T cells and improved the efficacy of cancer immunotherapy, compared to immunotherapy alone. Journal of Cancer Immunotherapy.
The Oxford vaccine technology, used to create the AstraZeneca vaccine for corona, produces strong cell responsesCD8 + T , which are necessary for good anti-tumor effects, the team developed a two-dose therapeutic vaccine with different primary and booster viral vectors, one of which is the same vector found in the Oxford-AstraZeneca corona vaccine..
In order to create a vaccine that specifically targets cancer cells, the vaccine is designed to target two types of proteins: MAGE Found on the surface of many types of cancer cells.
Preclinical trials in mouse tumor models showed that the cancer vaccine increased levels of infiltrating cells CD8 + T to the tumor and enhance the response to anti- . immunotherapy PD-1. Resulting from the combined vaccine and anti- . treatment PD-1 Greater reduction in tumor size and improved survival of mice compared to anti- . treatment PD-1 lonliness.
A phase 1/2 clinical trial of a cancer vaccine with anti-HIV immunotherapy will be launched PD-1 in 80 patients with non-small cell lung cancer later this year.